Interferon beta modulates endothelial damage in patients with cardiac persistence of human parvovirus B19 infection

Journal of Infectious Diseases

Volumn 201, Issue 6, 2010, Pages 936-945

  Schmidt Lucke, Caroline ^a   Spillmann, Frank ^a   Bock, Thomas ^c,d   Kühl, Uwe ^a   Van Linthout, Sophie ^a   Schultheiss, Heinz Peter ^a   Tschöpe, Carsten ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Brandenburg Center for Regenerative Therapies   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON;

ADULT; AGED; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ERYTHEMA INFECTIOSUM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE INJURY; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; APOPTOSIS; CARDIOVASCULAR DISEASES; CELL LINE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77749271186     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/650700     Document Type: Article

References (38)

1. Kuethe F, Sigusch HH, Hilbig K, et al. Detection of viral genome in the myocardium: lack of prognostic and functional relevance in patients with acute dilated cardiomyopathy. Am Heart J 2007; 153(5):850-858.
2. Schenk T, Enders M, Pollak S, Hahn R, Huzly D. High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy. J Clin Microbiol 2009; 47(1): 106-110.
3. Fabiana Corcioli KZ, Alessio Rinieri, Rosa Fanci, et al. Tissue persistence of parvovirus B19 genotypes in asymptomatic persons. J Med Virol 2008;80(11):2005-2011.
4. Kuhl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112(13):1965-1970.
5. Yilmaz A, Mahrholdt H, Athanasiadis A, et al. Coronary vasospasm as the underlying cause for chest pain in patients with PVB19-myocarditis. Heart 2008:94(11):1456-1463.
6. Bultmann BD, Klingel K, Sotlar K, et al. Fatal parvovirus B 19-associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. Hum Pathol 2003; 34:92-95.
7. Tschope C, Bock C-T, Kasner M, et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005; 111(7):879-886.
8. Vallbracht KB, Schwimmbeck PL, Kühl U, Rauch U, Seeberg B, Schultheiss H-P. Differential aspects of endothelial function of the coronary microcirculation considering myocardial virus persistence, endothelial activation, and myocardial leukocyte infiltrates. Circulation 2005;111(14):1784-1791.
9. Lupescu A, Bock C-T, Lang PA, et al. Phospholipase A2 activity-dependent stimulation of Ca2+ entry by human parvovirus B19 capsid protein VP1. J Virol 2006;80(22):11370-11380.
10. Moffat S, Yaegashi N, Tada K, Tanaka N, Sugamura K. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol 1998;72:3018-3028.
11. Hsu TC, Tzang BS, Huang CN, et al. Increased expression and secretion of interleukin-6 in human parvovirus B19 non-structural protein (NS1) transfected COS-7 epithelial cells. Clin Exp Immunol 2006; 144(1):152-157.
12. Fu Y, Ishii KK, Munakata Y, Saitoh T, Kaku M, Sasaki T. Regulation of tumor necrosis factor alpha promotor by human parvovirus B19 NS1 through activation of AP-1 and AP-2. J Virol 2002; 76:5395-5403.
13. Duechting A, Tschope Q Kaiser H, et al. Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells. J Virol 2008:82(16)7942-7952.
14. Poole BD, Karetny YV, Naides S. Parvovirus B19-induced apoptosis of hepatocytes. J Virol 2004; 78:7775-7783.
15. Poole BD, Zhou J, Grote A, Schiffenbauer A, Naides SJ. Apoptosis of liver-derived cells induced by parvovirus B19 nonstructural protein. J Virol 2006;80(8):4114-4121.
16. Fischer D, Rossa S, Landmesser U, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005;26(1):65-69.
17. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101(16):1899-1906.
18. Anderson T, Uehata A, Gerhard M, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26(5):1235-1241.
19. Dimmeler S, Haendeler J, Nehls M, Zeiher AM. Suppression of apoptosis by nitric oxide via inhibition of interleukin-lbeta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J Exp Med 1997; 185(4):601-608.
20. Asai K, Kudej RK, Shen Y-T, et al. Peripheral vascular endothelial dysfunction and apoptosis in old monkeys. Arterioscler Thromb Vasc Biol 2000; 20(6):1493-1499.
21. Mallat Z, Benamer H, Hugel B, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101(8):841-843.
22. Werner N, Wassmann S, Ahlers P, Kosiol S, Nickenig G. Circulating CD31+/annexin V+ apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2006;26(1):112-116. (Pubitemid 43732236)
23. Walter D, Rittig K, Bahlmann F, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002; 105(25):3017-3024.
24. Hoffmann J, Haendeler J, Aicher A, et al. Aging enhances the sensitivity of endothelial cells toward apoptotic stimuli: important role of nitric oxide. Circ Res 2001;89(8):709-715.
25. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003; 108(4): 457-463.
26. Schmidt-Lucke C, Rossig L, Fichtischerer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111(22):2981-2987.
27. Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: the scientific foundations of cardiac repair. J Clin Invest 2005; 115(3):572-583.
28. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006; 124(1):175-189.
29. Kuhl U PM, Schwimmbeck PL, Seeberg B, et al. Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003; 107:2793-2798.
30. Schultheiss HP, Piper C, Sowade O, et al. The effect of subcutaneous treatment with interferon-beta-lb over 24 weeks on safety, virus elemination and clinical outcom in patientes with chronic viral cardiomyopathy. Circulation 2008; 118(22):2312. http://circ.ahajournals.org/cgi/reprint/118/22/2309.pdf. Accessed 11 February 2010.
31. Kiss J, Yegutkin GG, Koskinen K, Savunen T, Jalkanen S, Salmi M. IFN-β protects from vascular leakage via up-regulation of CD73. Eur J Immunol 2007;37(12):3334-3338.
32. Ribeiro MJ, Phillips JD, Benson JM, Evatt BL, Ades EW, Hooper WC. Hemostatic properties of the SV-40 transfected human microvascular endothelial cell line (HMEC-1): a representative in vitro model for microvascular endothelium. Thromb Res 1995;79:153-161.
33. Hemauer A, Gigler A, Gareus R, Reichle A, Wolf H, Modrow S. Infection of apheresis cells by parvovirus B19. J Gen Virol 1999;80(pt 3):627-630.
34. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001;97:3658-3661.
35. Monestiroli S, Mancuso P, Burlini A, et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001;61:4341-4344.
36. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998;31(1): 1-9.
37. Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest 2000; 105(1):17-19.
38. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348(7): 593-600.